Are you Dr. Juergens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1650 Orleans St
Johns Hopkins Crb I -G93
Baltimore, MD 21287Phone+1 410-955-8893
Summary
- Dr. Rosalyn Juergens, MD is an oncologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland.
Certifications & Licensure
MD State Medical License 2003 - 2022
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer.Barbara Melosky, Rosalyn A Juergens, Shantanu Banerji, Adrian Sacher, Paul Wheatley-Price
Therapeutic Advances in Medical Oncology. 2025-01-01 - A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.Sze Wah Samuel Chan, Joy Zeng, Jack Young, Samir H Barghout, Faisal Al-Agha
Clinical Lung Cancer. 2025-01-01 - Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and M...Anthony M Brade, Houda Bahig, Andrea Bezjak, Rosalyn A Juergens, Charmaine Lynden
Current Oncology. 2024-10-23
Press Mentions
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (Lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a DecadeNovember 30th, 2021
Health Canada Approves Tecentriq(atezolizumab), First New Treatment in 20 Years for Aggressive Form of Lung Cancer(1)August 13th, 2019
Lung Cancer ‘Not One Big Disease’March 20th, 2018- Join now to see all
